---
title: "KEYNOTE-942 5-Year Update: Intismeran Autogene Plus Pembrolizumab vs Pembrolizumab in High‑Risk Re"
id: "pubmed-42223134"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-42223134"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/42223134/"
doi: "10.1200/JCO-26-00835"
published_at: "2026-09-10T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# KEYNOTE-942 5-Year Update: Intismeran Autogene Plus Pembrolizumab vs Pembrolizumab in High‑Risk Re
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-42223134
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/42223134/)
- **DOI:** [10.1200/JCO-26-00835](https://doi.org/10.1200%2FJCO-26-00835)
- **Published At:** 2026-09-10T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- This PubMed entry reports a 5-year update of the randomized Phase IIb **KEYNOTE-942** trial comparing **intismeran autogene plus pembrolizumab** versus pembrolizumab alone in patients with high‑risk resected melanoma. - The article is published in Journal of Clinical Oncology (J Clin Oncol), with final citation details: 2026 Sep 10;44(26):2482-2489; DOI 10.1200/JCO-26-00835; PMID 42223134. - The study is authored by Adnan Khattak et al. and lists multiple international investigators and affiliations across academic centres, cancer institutes, Merck, and Moderna. - The PubMed record identifies the work as a Clinical Trial and Phase IIb based on the title; the title indicates a randomized comparison and that this is a 5‑year update. - The PubMed page includes a link to the full text on the publisher site (Atypon/ASCOPubs) but the abstract or detailed results are not included in the provided JINA source text. - The PubMed metadata (authors, affiliations, journal, DOI, PMID, publication dates) are reported, but the SOURCE JINA BODY does not contain numeric outcomes, hazard ratios, survival rates, safety data, or statistical analyses; those details were not reported in the source. - Clinicians should consult the full text (publisher link provided) for efficacy, safety, and statistical results and for assessment of clinical implications of combining **intismeran autogene** with **pembrolizumab** in the adjuvant setting for high‑risk resected melanoma.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/42223134/#article-details) ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42223134%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/42223134/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/42223134/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/42223134/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/c24ab723-7c80-48cd-9c68-022ded852586/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/42223134/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/42223134/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/42223134/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42223134%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42223134%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/42223134/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42223134/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42223134/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/42223134/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Full text links [![Atypon full text link](https://cdn.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--ascopubs.org-pb-assets-pubmed-JCO_125x30.png) Atypon ](https://ascopubs.org/doi/10.1200/JCO-26-00835?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed "See full text options at Atypon") [ Full text links ](https://pubmed.ncbi.nlm.nih.gov/42223134/) ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42223134/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/42223134/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/42223134/#abstract) * [Similar articles](https://pubmed.ncbi.nlm.nih.gov/42223134/#similar) * [ Publication types ](https://pubmed.ncbi.nlm.nih.gov/42223134/#publication-types) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/42223134/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/42223134/#substances) * [ Associated data ](https://pubmed.ncbi.nlm.nih.gov/42223134/#supplemental-data) * [Related information](https://pubmed.ncbi.nlm.nih.gov/42223134/#related-links) * [ LinkOut - more resources ](https://pubmed.ncbi.nlm.nih.gov/42223134/#linkout) Title & authors Abstract Similar articles Publication types MeSH terms Substances Associated data Related information LinkOut - more resources Clinical Trial J Clin Oncol Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22J+Clin+Oncol%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22J+Clin+Oncol%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42223134/) . 2026 Sep 10;44(26):2482-2489. doi: 10.1200/JCO-26-00835. Epub 2026 Jun 1. # Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study [Adnan Khattak](https://pubmed.ncbi.nlm.nih.gov/?term=Khattak+A&cauthor_id=42223134)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42223134/#full-view-affiliation-1 "One Clinical Research, Hollywood Private Hospital and Edith Cowan University, Perth, WA, Australia."), [Matteo S Carlino](https://pubmed.ncbi.nlm.nih.gov/?term=Carlino+MS&cauthor_id=42223134)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42223134/#full-view-affiliation-2 "Westmead and Blacktown Hospitals, Melanoma Institute Australia, and The University of Sydney, Sydney, NSW, Australia."), [Tarek Meniawy](https://pubmed.ncbi.nlm.nih.gov/?term=Meniawy+T&cauthor_id=42223134)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42223134/#full-view-affiliation-3 "Saint John of God Subiaco Hospital, Subiaco, WA, Australia."), [George Ansstas](https://pubmed.ncbi.nlm.nih.gov/?term=Ansstas+G&cauthor_id=42223134)[ 4 ](https://pubmed.ncbi.nlm.nih.gov/42223134/#full-view-affiliation-4 "Washington University School of Medicine, St Louis, MO."), [Matthew H Taylor](https://pubmed.ncbi.nlm.nih.gov/?term=Taylor+MH&cauthor_id=42223134)[ 5 ](https://pubmed.ncbi.nlm.nih.gov/42223134/#full-view-affiliation-5 "Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR."), [Kevin B Kim](https://pubmed.ncbi.nlm.nih.gov/?term=Kim+KB&cauthor_id=42223134)[ 6 ](https://pubmed.ncbi.nlm.nih.gov/42223134/#full-view-affiliation-6 "California Pacific Medical Center Research Institute, San Francisco, CA."), [Meredith McKean](https://pubmed.ncbi.nlm.nih.gov/?term=McKean+M&cauthor_id=42223134)[ 7 ](https://pubmed.ncbi.nlm.nih.gov/42223134/#full-view-affiliation-7 "Sarah Cannon Research Institute, Nashville, TN."), [Georgina V Long](https://pubmed.ncbi.nlm.nih.gov/?term=Long+GV&cauthor_id=42223134)[ 8 ](https://pubmed.ncbi.nlm.nih.gov/42223134/#full-view-affiliation-8 "Melanoma Institute Australia, Royal North Shore and Mater Hospitals, The University of Sydney, Sydney, NSW, Australia."), [Ryan J Sullivan](https://pubmed.ncbi.nlm.nih.gov/?term=Sullivan+RJ&cauthor_id=42223134)[ 9 ](https://pubmed.ncbi.nlm.nih.gov/42223134/#full-view-affiliation-9 "Mass General Brigham Cancer Institute, Harvard Medical School, Boston, MA."), [Mark Faries](https://pubmed.ncbi.nlm.nih.gov/?term=Faries+M&cauthor_id=42223134)[ 10 ](https://pubmed.ncbi.nlm.nih.gov/42223134/#full-view-affiliation-10 "The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate, Los Angeles, CA."), [Thuy T Tran](https://pubmed.ncbi.nlm.nih.gov/?term=Tran+TT&cauthor_id=42223134)[ 11 ](https://pubmed.ncbi.nlm.nih.gov/42223134/#full-view-affiliation-11 "Smilow Cancer Center at Yale New Haven Hospital, New Haven, CT."), [C Lance Cowey](https://pubmed.ncbi.nlm.nih.gov/?term=Cowey+CL&cauthor_id=42223134)[ 12 ](https://pubmed.ncbi.nlm.nih.gov/42223134/#full-view-affiliation-12 "Texas Oncology PA, Dallas, TX."), [Andrew Pecora](https://pubmed.ncbi.nlm.nih.gov/?term=Pecora+A&cauthor_id=42223134)[ 13 ](https://pubmed.ncbi.nlm.nih.gov/42223134/#full-view-affiliation-13 "Hackensack University Medical Center, Hackensack, NJ."), [Theresa Medina](https://pubmed.ncbi.nlm.nih.gov/?term=Medina+T&cauthor_id=42223134)[ 14 ](https://pubmed.ncbi.nlm.nih.gov/42223134/#full-view-affiliation-14 "University of Colorado Cancer Center, Aurora, CO."), [Victoria Atkinson](https://pubmed.ncbi.nlm.nih.gov/?term=Atkinson+V&cauthor_id=42223134)[ 15 ](https://pubmed.ncbi.nlm.nih.gov/42223134/#full-view-affiliation-15 "Princess Alexandra Hospital, Brisbane, QLD, Australia."), [Clemens Krepler](https://pubmed.ncbi.nlm.nih.gov/?term=Krepler+C&cauthor_id=42223134)[ 16 ](https://pubmed.ncbi.nlm.nih.gov/42223134/#full-view-affiliation-16 "Merck & Co, Inc, Rahway, NJ."), [Thomas Jemielita](https://pubmed.ncbi.nlm.nih.gov/?term=Jemielita+T&cauthor_id=42223134)[ 16 ](https://pubmed.ncbi.nlm.nih.gov/42223134/#full-view-affiliation-16 "Merck & Co, Inc, Rahway, NJ."), [Huzhang Mao](https://pubmed.ncbi.nlm.nih.gov/?term=Mao+H&cauthor_id=42223134)[ 17 ](https://pubmed.ncbi.nlm.nih.gov/42223134/#full-view-affiliation-17 "Moderna, Inc, Cambridge, MA."), [Jacky Chow](https://pubmed.ncbi.nlm.nih.gov/?term=Chow+J&cauthor_id=42223134)[ 17 ](https://pubmed.ncbi.nlm.nih.gov/42223134/#full-view-affiliation-17 "Moderna, Inc, Cambridge, MA."), [Laureen S Ojalvo](https://pubmed.ncbi.nlm.nih.gov/?term=Ojalvo+LS&cauthor_id=42223134)[ 17 ](https://pubmed.ncbi.nlm.nih.gov/42223134/#full-view-affiliation-17 "Moderna, Inc, Cambridge, MA."), [Janice M Mehnert](https://pubmed.ncbi.nlm.nih.gov/?term=Mehnert+JM&cauthor_id=42223134)[ 18 ](https://pubmed.ncbi.nlm.nih.gov/42223134/#full-view-affiliation-18 "Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York, NY."); [KEYNOTE-942 Investigators](https://pubmed.ncbi.nlm.nih.gov/?term=KEYNOTE-942+Investigators%5BCorporate+Author%5D) Affiliations Expand ### Affiliations * 1 One Clinical Research, Hollywood Private Hospital and Edith Cowan University, Perth, WA, Australia. * 2 Westmead and Blacktown Hospitals, Melanoma Institute Australia, and The University of Sydney, Sydney, NSW, Australia. * 3 Saint John of God Subiaco Hospital, Subiaco, WA, Australia. * 4 Washington University School of Medicine, St Louis, MO. * 5 Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR. * 6 California Pacific Medical Center Research Institute, San Francisco, CA. * 7 Sarah Cannon Research Institute, Nashville, TN. * 8 Melanoma Institute Australia, Royal North Shore and Mater Hospitals, The University of Sydney, Sydney, NSW, Australia. * 9 Mass General Brigham Cancer Institute, Harvard Medical School, Boston, MA. * 10 The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate, Los Angeles, CA. * 11 Smilow Cancer Center at Yale New Haven Hospital, New Haven, CT. * 12 Texas Oncology PA, Dallas, TX. * 13 Hackensack University Medical Center, Hackensack, NJ. * 14 University of Colorado Cancer Center, Aurora, CO. * 15 Princess Alexandra Hospital, Brisbane, QLD, Australia. * 16 Merck & Co, Inc, Rahway, NJ. * 17 Moderna, Inc, Cambridge, MA. * 18 Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York, NY. * PMID: **42223134** * DOI: [ 10.1200/JCO-26-00835 ](https://doi.org/10.1200/jco-26-00835) Item in Clipboard Clinical Trial # Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study Adnan Khattak et al. J Clin Oncol. 2026. Show details Display options Display options Format Abstract PubMed PMID J Clin Oncol Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22J+Clin+Oncol%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22J+Clin+Oncol%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42223134/) . 2026 Sep 10;44(26):2482-2489. doi: 10.1200/JCO-26-00835. Epub 2026 Jun 1. ### Authors [Adnan Khattak](https://pubmed.ncbi.nlm.nih.gov/?term=Khattak+A&cauthor_id=42223134)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42223134/#short-view-affiliation-1 "One Clinical Research, Hollywood Private Hospital and Edith Cowan University, Perth, WA, Australia."), [Matteo S Carlino](https://pubmed.ncbi.nlm.nih.gov/?term=Carlino+MS&cauthor_id=42223134)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42223134/#short-view-affiliation-2 "Westmead and Blacktown Hospitals, Melanoma Institute Australia, and The University of Sydney, Sydney, NSW, Australia."), [Tarek Meniawy](https://pubmed.ncbi.nlm.nih.gov/?term=Meniawy+T&cauthor_id=42223134)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42223134/#short-view-affiliation-3 "Saint John of God Subiaco Hospital, Subiaco, WA, Australia."), [George Ansstas](https://pubmed.ncbi.nlm.nih.gov/?term=Ansstas+G&cauthor_id=42223134)[ 4 ](https://pubmed.ncbi.nlm.nih.gov/42223134/#short-view-affiliation-4 "Washington University School of Medicine, St Louis, MO."), [Matthew H Taylor](https://pubmed.ncbi.nlm.nih.gov/?term=Taylor+MH&cauthor_id=42223134)[ 5 ](https://pubmed.ncbi.nlm.nih.gov/42223134/#short-view-affiliation-5 "Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR."), [Kevin B Kim](https://pubmed.ncbi.nlm.nih.gov/?term=Kim+KB&cauthor_id=42223134)[ 6 ](https://pubmed.ncbi.nlm.nih.gov/42223134/#short-view-affiliation-6 "California Pacific Medical Center Research Institute, San Francisco, CA."), [Meredith McKean](https://pubmed.ncbi.nlm.nih.gov/?term=McKean+M&cauthor_id=42223134)[ 7 ](https://pubmed.ncbi.nlm.nih.gov/42223134/#short-view-affiliation-7 "Sarah Cannon Research Institute, Nashville, TN."), [Georgina V Long](https://pubmed.ncbi.nlm.nih.gov/?term=Long+GV&cauthor_id=42223134)[ 8 ](https://pubmed.ncbi.nlm.nih.gov/42223134/#short-view-affiliation-8 "Melanoma Institute Australia, Royal North Shore and Mater Hospitals, The University of Sydney, Sydney, NSW, Australia."), [Ryan J Sullivan](https://pubmed.ncbi.nlm.nih.gov/?term=Sullivan+RJ&cauthor_id=42223134)[ 9 ](https://pubmed.ncbi.nlm.nih.gov/42223134/#short-view-affiliation-9 "Mass General Brigham Cancer Institute, Harvard Medical School, Boston, MA."), [Mark Faries](https://pubmed.ncbi.nlm.nih.gov/?term=Faries+M&cauthor_id=42223134)[ 10 ](https://pubmed.ncbi.nlm.nih.gov/42223134/#short-view-affiliation-10 "The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate, Los Angeles, CA."), [Thuy T Tran](https://pubmed.ncbi.nlm.nih.gov/?term=Tran+TT&cauthor_id=42223134)[ 11 ](https://pubmed.ncbi.nlm.nih.gov/42223134/#short-view-affiliation-11 "Smilow Cancer Center at Yale New Haven Hospital, New Haven, CT."), [C Lance Cowey](https://pubmed.ncbi.nlm.nih.gov/?term=Cowey+CL&cauthor_id=42223134)[ 12 ](https://pubmed.ncbi.nlm.nih.gov/42223134/#short-view-affiliation-12 "Texas Oncology PA, Dallas, TX."), [Andrew Pecora](https://pubmed.ncbi.nlm.nih.gov/?term=Pecora+A&cauthor_id=42223134)[ 13 ](https://pubmed.ncbi.nlm.nih.gov/42223134/#short-view-affiliation-13 "Hackensack University Medical Center, Hackensack, NJ."), [Theresa Medina](https://pubmed.ncbi.nlm.nih.gov/?term=Medina+T&cauthor_id=42223134)[ 14 ](https://pubmed.ncbi.nlm.nih.gov/42223134/#short-view-affiliation-14 "University of Colorado Cancer Center, Aurora, CO."), [Victoria Atkinson](https://pubmed.ncbi.nlm.nih.gov/?term=Atkinson+V&cauthor_id=42223134)[ 15 ](https://pubmed.ncbi.nlm.nih.gov/42223134/#short-view-affiliation-15 "Princess Alexandra Hospital, Brisbane, QLD, Australia."), [Clemens Krepler](https://pubmed.ncbi.nlm.nih.gov/?term=Krepler+C&cauthor_id=42223134)[ 16 ](https://pubmed.ncbi.nlm.nih.gov/42223134/#short-view-affiliation-16 "Merck & Co, Inc, Rahway, NJ."), [Thomas Jemielita](https://pubmed.ncbi.nlm.nih.gov/?term=Jemielita+T&cauthor_id=42223134)[ 16 ](https://pubmed.ncbi.nlm.nih.gov/42223134/#short-view-affiliation-16 "Merck & Co, Inc, Rahway, NJ."), [Huzhang Mao](https://pubmed.ncbi.nlm.nih.gov/?term=Mao+H&cauthor_id=42223134)[ 17 ](https://pubmed.ncbi.nlm.nih.gov/42223134/#short-view-affiliation-17 "Moderna, Inc, Cambridge, MA."), [Jacky Chow](https://pubmed.ncbi.nlm.nih.gov/?term=Chow+J&cauthor_id=42223134)[ 17 ](https://pubmed.ncbi.nlm.nih.gov/42223134/#short-view-affiliation-17 "Moderna, Inc, Cambridge, MA."), [Laureen S Ojalvo](https://pubmed.ncbi.nlm.nih.gov/?term=Ojalvo+LS&cauthor_id=42223134)[ 17 ](https://pubmed.ncbi.nlm.nih.gov/42223134/#short-view-affiliation-17 "Moderna, Inc, Cambridge, MA."), [Janice M Mehnert](https://pubmed.ncbi.nlm.nih.gov/?term=Mehnert+JM&cauthor_id=42223134)[ 18 ](https://pubmed.ncbi.nlm.nih.gov/42223134/#short-view-affiliation-18 "Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York, NY."); [KEYNOTE-942 Investigators](https://pubmed.ncbi.nlm.nih.gov/?term=KEYNOTE-942+Investigators%5BCorporate+Author%5D) ### Affiliations * 1 One Clinical Research, Hollywood Private Hospital and Edith Cowan University, Perth, WA, Australia. * 2 Westmead and Blacktown Hospitals, Melanoma Institute Australia, and The University of Sydney, Sydney, NSW, Australia. * 3 Saint John of God Subiaco Hospital, Subiaco, WA, Australia. * 4 Washington University School of Medicine, St Louis, MO. * 5 Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR. * 6 California Pacific Medical Center Research Institute, San Francisco, CA. * 7 Sarah Cannon Research Institute, Nashville, TN. * 8 Melanoma Institute Australia, Royal North Shore and Mater Hospitals, The University of Sydney, Sydney, NSW, Australia. * 9 Mass General Brigham Cancer Institute, Harvard Medical School, Boston, MA. * 10 The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate, Los Angeles, CA. * 11 Smilow Cancer Center at Yale New Haven Hospital, New Haven, CT. * 12 Texas Oncology PA, Dallas, TX. * 13 Hackensack University Medical Center, Hackensack, NJ. * 14 University of Colorado Cancer Center, Aurora, CO. * 15 Princess Alexandra Hospital, Brisbane, QLD, Australia. * 16 Merck & Co, Inc, Rahway, NJ. * 17 Moderna, Inc, Cambridge, MA. * 18 Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New
## Related Clinical Research

- [Immune-pressure redistribution as a framework for resistance to PD-1/PD-L1 blockade](https://medichelpline.com/clinical-feed/pubmed-42763389.md) (DOI: 10.1186/s12943-026-02786-4)
- [Key 2025 Advances in Autologous Cellular Therapy for Melanoma and Solid Tumors](https://medichelpline.com/clinical-feed/pubmed-42734903.md) (DOI: 10.1002/cncr.70612)
- [Personalized mRNA vaccine plus pembrolizumab lowers melanoma recurrence in phase 3 trial](https://medichelpline.com/clinical-feed/medical-news-today-0-novel-mrna-vaccine-plus-immunotherapy-reduces-melanoma-relapse-in-phase-3-trial.md)
- [Challenging FDA-Approved Cancer Drug Dosages: A Patient and Research Perspective](https://medichelpline.com/clinical-feed/kff-health-news-2-how-much-of-a-cancer-drug-is-too-much-patients-researchers-challenge-fda.md)
- [Insufficiently reported: tumor-infiltrating immune cell predictors of recurrence in melanoma after](https://medichelpline.com/clinical-feed/frontiers-in-immunology-15-tumor-infiltrating-immune-cell-types-predicting-recurrence-free-survival-in.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.